Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Shamash

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Surgical Oncology|March 20, 2009
Future directions in non-endocrine systemic treatment of metastatic prostate cancerJonathan Shamash
Expert Review of Anticancer Therapy|January 17, 2023
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?Jonathan Shamash, Kenrick Ng
Oncology and Therapy|July 24, 2020
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line SettingKenrick Ng, Shievon Smith, Jonathan Shamash
European Journal of Cancer (Oxford, England : 1990)|April 5, 2018
Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.' by Loriot and colleaguesConstantine Alifrangis, Peter Wilson, Jonathan Shamash
The New England Journal of Medicine|October 26, 2007
Germ-cell tumorsJonathan Shamash, Justin Stebbing, Thomas Powles
Journal of HIV Therapy|October 27, 2007
Prostate cancer in HIV-positive individuals: what we know and what we don'tZoe Walters, Jonathan Shamash, Thomas Powles
Lancet (London, England)|January 16, 2004
Erythropoietin to treat anaemia in patients with head and neck cancerThomas Powles, Jonathan Shamash, Wai Liu
Expert Review of Anticancer Therapy|March 21, 2018
Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversiesKenrick Ng, Sarah Duncan, Jonathan Shamash, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapyMarco Gerlinger, Peter Wilson, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2020
Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practiceDaniel M Berney, Jonathan Shamash, Sara Stoneham, et al.
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Surgical Oncology|March 20, 2009
Future directions in non-endocrine systemic treatment of metastatic prostate cancerJonathan Shamash
Expert Review of Anticancer Therapy|January 17, 2023
Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?Jonathan Shamash, Kenrick Ng
Oncology and Therapy|July 24, 2020
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line SettingKenrick Ng, Shievon Smith, Jonathan Shamash
European Journal of Cancer (Oxford, England : 1990)|April 5, 2018
Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment of brain metastases.' by Loriot and colleaguesConstantine Alifrangis, Peter Wilson, Jonathan Shamash
The New England Journal of Medicine|October 26, 2007
Germ-cell tumorsJonathan Shamash, Justin Stebbing, Thomas Powles
Journal of HIV Therapy|October 27, 2007
Prostate cancer in HIV-positive individuals: what we know and what we don'tZoe Walters, Jonathan Shamash, Thomas Powles
Lancet (London, England)|January 16, 2004
Erythropoietin to treat anaemia in patients with head and neck cancerThomas Powles, Jonathan Shamash, Wai Liu
Expert Review of Anticancer Therapy|March 21, 2018
Dose intense chemotherapy in the management of poor prognosis and relapsed testicular cancer: experiences and controversiesKenrick Ng, Sarah Duncan, Jonathan Shamash, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapyMarco Gerlinger, Peter Wilson, Thomas Powles, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2020
Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practiceDaniel M Berney, Jonathan Shamash, Sara Stoneham, et al.
Pageof 11